American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Apply for this position
Open Access
Journal Browser
American Journal of Medical Case Reports. 2015, 3(8), 250-254
DOI: 10.12691/ajmcr-3-8-8
Open AccessCase Report

A Case of Symptomatic Inflammatory Tongue Treated with Fucoidan

Shuichi Tsubura1, , Yoshie Waki2 and Tsutomu Tsubura2

1Department of Biochemistry, Nippon Dental University School of Life Dentistry at Niigata, Hamaura-cho, chuo-ku, Niigata, Japan

2Tsubura Dental Clinic, Utsunomiya, Tochigi, Japan

Pub. Date: July 16, 2015

Cite this paper:
Shuichi Tsubura, Yoshie Waki and Tsutomu Tsubura. A Case of Symptomatic Inflammatory Tongue Treated with Fucoidan. American Journal of Medical Case Reports. 2015; 3(8):250-254. doi: 10.12691/ajmcr-3-8-8


Abnormalities of symptomatic inflammatory tongue (SIT) present a diagnostic and therapeutic dilemma for clinicians. In particular, atrophic glossitis or fissured tongue is often linked to underlying semi-pathological conditions such as immunodeficiency, nutritional deficiency, or the effects of pharmacotherapy. The various therapies for this condition include corticosteroid ointment, anesthetic gel, anti-inflammatory drugs, and vitamin B12 supplementation to address the symptoms. However, none of these treatments has been evaluated rigorously. The case of an adult patient in which persistent, painful SIT was successfully treated using a 32% fucose chewable tablet is presented. In this case, PC-320TM achieved marked improvements in SIT. Clinical trials are needed to confirm the efficacy and safety of topical PC-320 in treating SIT.

tongue fucoidan inflammation treatment tablet

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Shulman, J.D., Beach, M.M and Rivera-Hidalgo, F., “The prevalence of oral mucosal lesions in U.S. adults: data from the Third National Health and Nutrition Examination Survey, 1988-1994,” J Am Dent Assoc, 135(9). 1279-86. Sep. 2004.
[2]  Kylin, H., “Biochemistry of seaweeds,” Z Physiol Chem, 101: 236-45. 1918.
[3]  Berteau, O. and Mulloy, B., “Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide,” Glycobiology,13(6). 29-40. Jun. 2003.
[4]  Ribeiro, A.C., Vieira, R.P., Mourao, P.A.S. and Muloy B, “A sulfated alpha-L-fucan from sea cucumber,” Carbohydr Res, 255(4):225-40. Mar. 1994.
[5]  Byrd, J.A., Bruce, A.J. and Rogers, R.S. III, “Glossitis and other tongue disorders,” Dermatol Clin, 21 (1). 123-34. Jun. 2003.
[6]  Drage, L.A. and Rogers, R.S. III, “Burning mouth syndrome,” Dermatol Clin, 21(1). 135-45. 2003.
[7]  Siddhanta, A.K. and Murthy, A.S.K., “Bioactive polysaccharides from marine brown algae (Phaeophyceae),” J Indian Chem Soc, 78. 431-7. 2001.
[8]  Aisa, Y., “Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways,” Am J Hematol, 78(1) .7-14. Jun. 2005.
[9]  Senni, K., Gueniche, F., Foucault-Bertaud, A., Igondjo-Tchen, S., Fioretti, F., Colliec-Jouault, S., Durand, P., Guezennec, J., Godeau, G. and Letourneur, D., “Fucoidan a sulfated polysaccharide from brown algae is a potent modulator of connective tissue proteolysis,” Arch Biochem Biophys, 445(1). 56-64. Jan. 2006.
[10]  Moon, H.J., Lee, S.H., Ku, M.J., Yu, B.C., Jeon, M.J., Jeong, S.H., Stonik, V.A., Zvyagintseva, T.N., Ermakova, S.P. and Lee, Y.H., “Fucoidan inhibits UVB-induced MMP-1 promoter expression and down regulation of type I procollagen synthesis in human skin fibroblasts,” Eur J Dermatol, 19(2). 129-34. Mar-Apr. 2009.